Allergan completes acquisition of ZELTIQ Aesthetic

Allergan announced that it has completed the acquisition of ZELTIQ Aesthetics for $2.4 billion cash. ZELTIQ stockholders approved the transaction during the meeting held on April 27, 2017.

Allergan Chief Commercial Officer, Bill Meury said that they are thrilled to complete the acquisition of ZELTIQ, which immediately expands their world-class global aesthetic business into the highly-complementary and fast-growing body contouring segment. CoolSculpting gives Allergan the most comprehensive and dynamic portfolio of products for plastic surgeons, dermatologists and other aesthetic providers across the globe.

The CoolSculpting System has been cleared by the U.S. FDA, with global IP rights, to affect appearance through lipolysis or reduction of unwanted fat using a patented cooling technology. CoolSculpting is marketed in more than 80 countries with entry into additional markets expected in 2017 and 2018. CoolSculpting works by gently cooling targeted fat cells in the body to induce a natural, controlled elimination of fat cells without affecting surrounding tissue.